Author

Donatello Salvatore

Cystic Fibrosis Center, Hospital San Carlo, Potenza, Italy - Cited by 1,513 - cystic fibrosis

Biography

Dr Donatello Salvatore is the Head of UOSD Center for the treatment of Cystic Fibrosis of the Basilicata Region. And he is also Member of the scientific committee of the Italian Cystic Fibrosis Registry, Itlay.
Title
Cited by
Year
Genotype–phenotype correlation and functional studies in patients with cystic fibrosis bearing CFTR complex alleles
V Terlizzi, G Castaldo, D Salvatore, M Lucarelli, V Raia, A Angioni, ...Journal of Medical Genetics 54 (4), 224-235, 2017201
57
2017
Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND …
PA Flume, RF Biner, DG Downey, C Brown, M Jain, R Fischer, ...The Lancet Respiratory Medicine 9 (7), 733-746, 2021202
38
2021
Clinical expression of cystic fibrosis in a large cohort of Italian siblings
V Terlizzi, M Lucarelli, D Salvatore, A Angioni, A Bisogno, C Braggion, ...BMC Pulmonary Medicine 18, 1-8, 2018201
32
2018
Update of literature from cystic fibrosis registries 2012–2015. Part 6: Epidemiology, nutrition and complications
D Salvatore, R Buzzetti, G MastellaPediatric pulmonology 52 (3), 390-398, 2017201
27
2017
Ivacaftor improves lung disease in patients with advanced CF carrying CFTR mutations that confer residual function
D Salvatore, V Terlizzi, M Francalanci, G Taccetti, B Messore, C Biglia, ...Respiratory Medicine 171, 106073, 2020202
22
2020
Elexacaftor/Tezacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for the F508del Mutation and Advanced Lung Disease: A 48-Week Observational Study
V Carnovale, P Iacotucci, V Terlizzi, C Colangelo, L Ferrillo, A Pepe, ...Journal of Clinical Medicine 11 (4), 1021, 2022202
18
2022
Patients with cystic fibrosis having a residual function mutation: Data from the Italian registry
D Salvatore, R Padoan, R Buzzetti, A Amato, B Giordani, G Ferrari, F MajoPediatric Pulmonology 54 (2), 150-157, 2019201
17
2019
Effectiveness and safety of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease with the Phe508del/minimal function genotype
V Carnovale, P Iacotucci, V Terlizzi, C Colangelo, P Medio, L Ferrillo, ...Respiratory Medicine 189, 106646, 2021202
16
2021
Treatment compliance in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection treated with tobramycin inhalation powder: the FREE study
F Blasi, V Carnovale, G Cimino, V Lucidi, D Salvatore, B Messore, ...Respiratory Medicine 138, 88-94, 2018201
15
2018
Italian Cystic Fibrosis Registry (ICFR). Report 2015-2016
B Giordani, A Amato, F Majo, G Ferrari, S Quattrucci, L Minicucci, ...Epidemiologia e Prevenzione 43 (4S1), 1-36, 2019201
14
2019
Elexacaftor–tezacaftor–ivacaftor therapy for cystic fibrosis patients with the F508del/unknown genotype
M Comegna, V Terlizzi, D Salvatore, C Colangelo, AM Di Lullo, I Zollo, ...Antibiotics 10 (7), 828, 2021202
13
2021
Effectivenesss of ivacaftor in severe cystic fibrosis patients and non‐G551D gating mutations
D Salvatore, V Carnovale, P Iacotucci, C Braggion, C Castellani, ...Pediatric Pulmonology 54 (9), 98-1403, 2019201
13
2019
Effectiveness of elexacaftor/tezacaftor/ivacaftor therapy in three subjects with the cystic fibrosis genotype Phe508del/unknown and advanced lung disease
V Terlizzi, C Colangelo, G Marsicovetere, M D’Andria, M Francalanci, ...Genes (8), 1178, 2021202
12
2021
High frequency and diversity of tetracycline resistance genes in the microbiota of broiler chickens in Tunisia
A Di Francesco, D Salvatore, S Sakhria, E Catelli, C Lupini, MS Abbassi, ...Animals (2), 377, 2021202
11
2021
Clinical outcomes of a large cohort of individuals with the F508del/5T; TG12 CFTR genotype
Clinical outcomes of a large cohort of individuals with the F50del/5T; TG12 CFTR genotypeA Tosco, A Castaldo, C Colombo, L Claut, V Carnovale, P Iacotucci, ...Journal of Cystic Fibrosis 21 (5), 50-55, 2022202
8
2022
Italian Cystic Fibrosis Registry (ICFR). Report 2017-2018
Italian Cystic Fibrosis Registry (ICFR). Report 201-2018G Campagna, A Amato, F Majo, G Ferrari, S Quattrucci, R Padoan, ...Epidemiologia e Prevenzione 45 (3 Suppl 1), 1-3, 2021202
7
2021
The diagnosis of cystic fibrosis in adult age. Data from the Italian registry
R Padoan, S Quattrucci, A Amato, V Carnovale, D Salvatore, M Salvatore, ...Diagnostics 11 (2), 321, 2021202
6
2021
Italian Cystic Fibrosis Registry (ICFR). Report 2019-2020
G Campagna, A Amato, F Majo, G Ferrari, S Quattrucci, R Padoan, ...Epidemiol Prev, 1-38, 2022202
4
2022
Elexacaftor/tezacaftor/ivacaftor for CFTR variants giving rise to diagnostic uncertainty: Personalised medicine or over-medicalisation?
D Salvatore, A Pepe, V Carnovale, F Majo, R Padoan, S Quattrucci, ...Journal of Cystic Fibrosis 21 (3), 5-58, 2022202
4
2022
First and second wave of SARS-CoV2 in Italian cystic fibrosis patients: data from Italian cystic fibrosis registry
R Padoan, V Carnovale, D Salvatore, S Quattrucci, D Taruscio, G Floridia, ...Journal of Cystic Fibrosis 20 (2), 372-373, 2021202
4
2021

Referred From: https://scholar.google.it/citations?user=p-t5WdEAAAAJ&hl=it

Cited by
Citations 1513
h-index 22
i10-index 40
Recommended Journals
Open Access Journals